In short
Recent clinical trials are investigating the use of Oxygen Ph.eur. in premature infants to improve their health outcomes and development. These studies focus on determining the optimal oxygen concentration for resuscitation at birth and exploring automatic oxygen control systems. The research aims to enhance neurodevelopmental outcomes, reduce complications associated with prematurity, and potentially decrease mortality rates in this vulnerable population.
At a glance
- Study Population
- Premature infants born between 23-28 weeks gestation
- Main Objectives
- Evaluate effects of different oxygen concentrations and automatic oxygen control on neurodevelopmental outcomes and complications of prematurity
- Primary Outcomes
- Mortality, neurodevelopmental impairment, severe retinopathy of prematurity, chronic lung disease, necrotizing enterocolitis
- Intervention
- Comparison of 30% vs 60% oxygen at birth; Closed-loop automatic control of oxygen vs manual adjustments
- Follow-up Period
- 18-24 months corrected age
- Potential Benefits
- Improved neurodevelopmental outcomes, reduced complications, potentially decreased mortality
What is OXYGEN PH.EUR.?
OXYGEN PH.EUR., also known as Medical Oxygen, is a medicinal gas used in healthcare settings, particularly for premature infants. It is a compressed gas that contains pure oxygen, which is essential for breathing and maintaining life. The term "PH.EUR." stands for "European Pharmacopoeia," indicating that the oxygen meets specific quality standards for medical use in Europe.
Medical Uses
OXYGEN PH.EUR. is primarily used in the treatment of premature infants, especially those born between 23 and 28 weeks of gestation. These extremely preterm infants often require respiratory support due to their underdeveloped lungs. The medical oxygen helps in:
- Supporting breathing and preventing apnea (temporary pauses in breathing)
- Maintaining adequate oxygen levels in the blood
- Assisting with various forms of respiratory support, such as mechanical ventilation or continuous positive airway pressure (CPAP)
Administration
OXYGEN PH.EUR. is administered through inhalation. In premature infants, it is typically delivered through specialized equipment such as ventilators or CPAP machines. The concentration of oxygen can be adjusted based on the infant's needs, ranging from 21% (room air) up to 100% pure oxygen.
Ongoing Research
Several clinical trials are currently investigating the optimal use of OXYGEN PH.EUR. in premature infants. These studies aim to improve outcomes and reduce potential complications associated with oxygen therapy. Two notable trials include:
- The HiLo-Trial: This study compares the effects of using 30% versus 60% oxygen concentration at birth on neurodevelopmental outcomes in very low birthweight infants. The researchers are investigating whether higher or lower initial oxygen levels can improve development at 18-24 months of age.
- Closed-loop Automatic Control Trial: This research evaluates the effectiveness of an automatic system for controlling oxygen levels in extremely preterm infants, compared to manual adjustments. The study aims to determine if this automated approach can reduce complications and improve outcomes.
Potential Benefits and Risks
While OXYGEN PH.EUR. is crucial for the survival of many premature infants, its use must be carefully balanced. Potential benefits include:
- Improved survival rates
- Better neurodevelopmental outcomes
- Support for underdeveloped lungs
However, there are also risks associated with oxygen therapy, which researchers are trying to minimize. These potential complications include:
- Retinopathy of prematurity (ROP): An eye disorder that can lead to vision problems
- Bronchopulmonary dysplasia (BPD): A chronic lung condition in premature infants
- Necrotizing enterocolitis (NEC): A serious intestinal condition
Conclusion
OXYGEN PH.EUR. plays a vital role in the care of premature infants, supporting their breathing and development. Ongoing research aims to optimize its use, balancing the benefits of oxygen therapy with potential risks. As medical knowledge advances, the goal is to provide the best possible outcomes for these vulnerable patients.